Skip to content
Novartis logo

Novartis India

EVONILE NSE
₹1,714.30
P/E
43.28
View as Markdown
MCP
Close 4 Nov 2026 ₹1,714.30 +762.75 +80.2% since 11 Mar 2026
Start ₹951.55

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
16.30%
Debt to Equity
0.00
EPS (TTM)
₹39.61
Book Value
₹331.23
Market Cap
—
P/E (TTM)
43.28
P/B
5.18
ROE
11.60%
Dividend Yield
1.45%
EBITDA
₹133 Cr
52W High
₹2,588.80
52W Low
₹909.70
Day Range
₹1,600.10 – ₹1,738.00
Volume
77,675

Peer Comparison

Healthcare › Pharmaceuticals

Novartis peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Novartis (this company)
₹1,714.3043.28₹4,257 Cr5.181.45%11.60%16.30%₹371 Cr₹97 Cr
Median 8 companies₹1,743.8541.05₹1,25,337 Cr4.980.70%16.25%17.05%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

55 Good

Data confidence 100/100

Category scores

Quality
46
Average
Returns, margins, earnings quality 22% weight
Valuation
50
Average
Cheap vs sector & own history 24% weight
Growth
24
Poor
Sales & profit trajectory 9% weight
Financial Health
85
Strong
Solvency, leverage, coverage 9% weight
Momentum
98
Strong
Trend strength, vol-adjusted 12% weight
Ownership
51
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 66.6%

Weaknesses

3
  • The company has delivered a poor sales growth of -1.46% over past five years.
  • Company has a low return on equity of 11.9% over last 3 years.
  • Earnings include an other income of Rs.36.9 Cr.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish865
OscillatorsBearish261
Moving AveragesStrong Bearish604

Key readings

RSI (14)
40.33
Neutral
MACD (12,26,9)
−51.59
Bearish
SMA (50)
1,862.66
Bearish
SMA (200)
1,321.70
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y−6.46%
5Y−1.46%
3Y−2.25%
1Y−0.56%
TTM+5.40%

Net profit

Net profit growth by window
10Y−7.28%
5Y+34.66%
3Y−3.35%
1Y−7.92%
TTM−4.90%

Operating cash flow

Operating cash flow growth by window
10Y−1.91%
5YTurned positive
3Y+1.46%
1Y−37.33%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+21.62 pp
5Y+19.46 pp
3Y+9.40 pp
1Y+0.99 pp
TTM+0.50 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹656 Cr
Mar 2018₹564 Cr
Mar 2019₹491 Cr
Mar 2020₹438 Cr
Mar 2021₹381 Cr
Mar 2022₹400 Cr
Mar 2023₹379 Cr
Mar 2024₹335 Cr
Mar 2025₹356 Cr
Mar 2026₹354 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹57.00 Cr
Mar 2018₹78.00 Cr
Mar 2019₹52.00 Cr
Mar 2020₹10.00 Cr
Mar 2021₹21.00 Cr
Mar 2022−₹4.00 Cr
Mar 2023₹103 Cr
Mar 2024₹85.00 Cr
Mar 2025₹101 Cr
Mar 2026₹93.00 Cr

AI Analysis — Bull vs Bear

Generated 31 Jul 2026
AI opinion · based on fundamentals
Risk medium

Novartis India Ltd is a nearly debt-free healthcare company with a market cap of Rs.3,933 Cr trading at a PE of 39.7x. The stock has delivered a 61% return over the past year despite underlying sales declining at -2% CAGR over 3 years and profit declining at -3% CAGR over the same period.

Bull Case 7
  • Company is virtually debt-free, providing strong balance sheet resilience and financial flexibility
  • Stock has delivered 61% returns over the past 1 year, reflecting strong market re-rating
  • 3-year stock CAGR of 29% significantly outpaces underlying earnings growth, indicating investor confidence in turnaround potential
  • ROE has improved to 12% in the last year from a 10-year average of 8%, showing improving capital efficiency
  • Dividend yield of 1.59% provides income support, relatively attractive for a healthcare company
  • 5-year compounded profit CAGR of 35% indicates the company has delivered strong bottom-line expansion over the medium term
  • Backed by global parent Novartis AG, providing access to a pipeline of patented therapies and operational expertise
Bear Case 7
  • Sales have declined at -2% CAGR over 3 years and -6% CAGR over 10 years, indicating a structurally shrinking revenue base
  • TTM profit growth is negative at -5%, indicating near-term earnings deterioration
  • ROE of 11.9% over 3 years is low for a pharma company with negligible debt, suggesting suboptimal capital deployment
  • Other income of Rs.36.9 Cr forms a significant portion of earnings, meaning core operating profitability may be overstated
  • 10-year compounded profit CAGR of -7% reflects long-term structural decline in earnings power
  • Price-to-book ratio of 4.75x is high relative to the modest ROE of 12%, implying expensive valuation on asset basis
  • TTM sales growth of just 5% after years of decline does not yet confirm a sustained revenue recovery

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

96d ago

TL;DR: Novartis India has undergone a complete change of control, with ChrysCapital-led investors acquiring 70.68% from Novartis AG and reconstituting the board. The key forward-looking question is whether ChrysCapital's new management can unlock value through a refreshed strategy, though execution under new ownership remains uncertain.

Positives 1
  • ChrysCapital acquires 70.68% stake Jul 29

    WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners acquired a combined 70.68% stake in Novartis India Limited, as disclosed in a SEBI SAST filing on July 29, 2026.

Neutral 2
  • Board reconstituted post takeover Jul 29

    Novartis India's board was reconstituted on July 29, 2026, with six new directors appointed and six outgoing directors resigning following ChrysCapital's acquisition of control from Novartis AG.

  • Open offer sees minimal acceptance Jul 10

    The open offer by WaveRise, ChrysCapital, and Two Infinity concluded with only 40 shares tendered at ₹860.64 per share, indicating existing shareholders largely preferred to hold their positions.

Quarterly Results

₹ Cr
EVONILE quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
91
79
85
81
92
87
93
84
88
90
86
91
104
Expenses
73
62
65
70
68
69
67
60
60
66
64
70
69
Operating Profit
17
17
20
11
24
18
26
24
27
24
22
21
35
OPM %
19%
21%
23%
14%
26%
21%
28%
29%
31%
26%
26%
23%
34%
Other Income
12
17
22
10
10
10
11
11
11
9
9
10
9
Interest
0
1
0
0
0
0
0
0
0
0
1
0
0
Depreciation
2
1
0
0
1
1
1
1
1
1
0
0
0
PBT
28
32
41
21
34
28
35
34
37
33
30
30
43
Tax %
27%
27%
36%
31%
24%
26%
28%
14%
26%
26%
46%
16%
25%
Net Profit
20
24
27
15
26
20
25
29
28
24
16
25
32
EPS (₹)
8.21
9.59
10.76
5.95
10.42
8.27
10.31
11.87
11.19
9.81
6.52
10.23
13.05

Profit & Loss

₹ Cr
EVONILE profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
870
690
656
564
491
438
381
400
379
335
356
354
371
Expenses
874
656
631
570
478
426
355
373
314
270
265
260
269
Operating Profit
−4
34
25
−6
12
12
27
27
65
65
91
94
102
OPM %
−0.4%
5%
3.8%
−1.1%
2.5%
2.8%
7%
7%
17%
19%
26%
27%
27%
Other Income
101
207
71
172
78
36
33
−17
58
62
42
39
37
Interest
0
0
1
6
2
6
8
5
2
1
1
1
1
Depreciation
4
3
4
3
3
13
12
10
6
3
2
2
2
PBT
93
237
92
158
86
29
40
−4
115
123
130
130
136
Tax %
15%
16%
38%
50%
40%
65%
48%
−3%
10%
31%
23%
28%
—
Net Profit
79
198
57
78
52
10
21
−4
103
85
101
93
98
EPS (₹)
24.75
62.04
20.33
31.74
20.97
4.08
8.46
−1.51
41.86
34.5
40.87
37.74
39.61
Div. Payout %
40%
16%
49%
32%
48%
245%
118%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
113%
72%
61%
66%
—

Balance Sheet

₹ Cr
EVONILE balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
14
12
12
12
12
12
12
12
12
12
Reserves
986
1,178
906
721
747
708
699
679
763
732
773
805
Borrowings
0
0
0
0
0
68
62
24
22
7
5
3
Other Liabilities
244
239
230
377
223
289
229
242
186
173
158
157
Total Liabilities
1,246
1,433
1,150
1,111
982
1,078
1,002
958
983
925
948
978
Fixed Assets
8
6
6
5
15
76
64
24
19
7
5
3
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
1,238
1,426
1,144
1,106
967
1,001
938
934
964
918
943
975
Total Assets
1,246
1,433
1,150
1,111
982
1,078
1,002
958
983
925
948
978

Cash Flow

₹ Cr
EVONILE cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−60
57
−41
161
−194
−23
−69
39
45
113
75
47
Investing
719
−630
424
69
274
56
95
87
−153
33
−3
18
Financing
−38
−39
−332
−268
−30
−41
−37
−36
−30
−121
−64
−64
Net Cash Flow
622
−612
51
−38
50
−9
−11
90
−139
26
7
0
Free Cash Flow
−64
54
−44
160
−208
−24
−69
38
45
113
75
46
CFO/EBITDA
601
398
13
−3,503
−1,210
124
−127
210
65
115
99
87

Ratios

EVONILE financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
35
27
23
28
34
31
37
41
35
45
41
38
Inventory Days
103
92
104
84
111
117
119
117
99
82
74
98
Days Payable
98
89
87
158
168
145
137
148
108
112
93
101
Cash Conversion Cycle
40
30
40
−45
−23
3
19
10
26
15
22
36
Working Capital Days
6
−35
−14
−99
7
−1
62
−23
−37
−59
−45
−46
ROCE %
9%
22%
9%
17%
12%
5%
6%
6%
15%
16%
17%
16%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Novartis insights

63 extracted metrics across FY05–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 70.68%
  • Public 21.29%
  • Others 5.31%
  • DIIs 1.50%
  • FIIs 1.22%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Documents

Frequently Asked Questions about Novartis India

What does Novartis India Ltd do?
Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. It imports various medicines to India from different sources across the globe.
Where is Novartis India Ltd (EVONILE) listed?
Novartis India Ltd trades as EVONILE on the NSE and under code 500672 on the BSE.
Which sector does Novartis India Ltd belong to?
Novartis India Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Novartis India Ltd?
Novartis India Ltd trades at a PE ratio of 43.28 as of 4 Nov 2026, on earnings per share of ₹39.61, against a book value of ₹331.23 per share.
What is the 52-week high and low of Novartis India Ltd?
Over the last 52 weeks Novartis India Ltd has traded between ₹909.7 and ₹2,588.8 as of 4 Nov 2026.
Does Novartis India Ltd pay dividends?
Novartis India Ltd has a dividend yield of 1.45%.
What is the Return on Equity (ROE) of Novartis India Ltd?
Novartis India Ltd reported a return on equity of 11.60%. Its debt-to-equity ratio is 0.00.

Company Information

Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. It imports various medicines to India from different sources across the globe.

Website novartis.in
CEO Ms. Shilpa Shashank Joshi
Employees 56
Listed 20 Apr 2026
Face Value ₹5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/EVONILE.md for Novartis India Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month